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Background/aim: Glanzmann thrombasthenia (GT) is a rare autosomal recessively inherited bleeding disorder characterized by the
quantitative (type 1 and type 2) or qualitative (type 3) deficiency in platelet membrane glycoprotein (GP) IIb/IIIa (CD41a/CD61)
fibrinogen receptors. In type 1, 2, and 3, CD41a/CD61 expression is 5%, 5%–20% and above 20%, respectively. In this study, diagnosis
of GT was confirmed and subgroups were identified in 32 Turkish patients by flow cytometry analysis.
Materials and methods: CD41a/CD61 expression levels in platelet-rich plasma (PRP) obtained from peripheral venous EDTA blood
samples were analyzed with a BD FACSCanto II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). GT subgroup analysis
was performed by counting 50,000 events in the BD FACSDiva Software v6.1.3 program of the instrument.
Results: In the present study, in blood samples of 32 patients from 23 families with GT and 22 healthy controls, co-expression levels of
CD41a and CD61 in PRP was analyzed. 12 out of 23 families were consistent with type 1 GT (52.2%), 4 were consistent with type 2 GT
(17.4%), and 7 were consistent with type 3 GT (30.4%).
Conclusion: Especially due to consanguineous marriages, GT with various glycoprotein levels may be detected. As a result of the
flow cytometry analysis of the present study with the highest GT patient population in Turkey, type 1 GT patients were the most
common subgroup. In the determination of the GT subgroups; especially in the detection of type 3 GT, flow cytometry is the most
sensitive glycoprotein analysis method. In addition to light transmission aggregometry, CD41a/CD61 study by flow cytometer confirms
diagnosis when mutation analysis cannot be performed.
Key words: Glanzmann thrombasthenia, glycoprotein IIb/IIIa, flow cytometry, platelet-rich plasma

1. Introduction
Glanzmann thrombasthenia (GT) was first described by
Eduard Glanzmann in 1918 as “hereditary hemorrhagic
thrombasthenia” [1]. GT is an autosomal recessive bleeding
disorder. The disorder is characterized in that platelets fail
to bind to fibrinogens and are unable to form aggregates
in the presence of a range of physiological agonists such
as adenosine diphosphate (ADP), thrombin, epinephrine,

or collagen. The apparent defect in patients is caused by
mutations in the genes (ITGA2B or ITGB3) encoding
GP IIb (αIIb) or GP IIIa (β3) proteins of the GP IIb/IIIa
complexes on the platelet surface [2–4].
GP IIb/IIIa receptors account for approximately
15% of total proteins on the platelet surface. Although
GT is a rare disorder, it is the best known of hereditary
disorders of platelet function [4]. The thrombasthenic
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phenotype is associated with quantitative or qualitative
abnormalities of the αIIbβ3 integrin platelet fibrinogen
receptor through the incorporation of platelets in the
formation of thrombus or aggregate in the area of vascular
injury [5]. Thrombasthenic platelets adhere to the affected
subendothelial tissue and secrete from depot granules.
However, successive reactions of platelets spreading on the
affected surface and thrombus formation are damaged [6].
The classification of GT is based on the content of
platelet alpha granules, the degree of fibrinogen and clot
retraction, and the expression level of CD41a/CD61. GT
has three subgroups, including type 1, type 2, and type 3
[5,7,8].
Type 1 GT is the most common subgroup with
CD41a/CD61 expression levels below 5% and low levels of
fibrinogen in alpha granules of activated platelets that bind
poorly to fibrinogen [7,9].
Patients with type 2 GT have a CD41a/CD61 expression
level of 5%–20% in their platelets. These patients have
significant platelet alpha granule fibrinogen and normal or
moderate clot retraction [7]. The presence of the fibrinogen
storage pool is consistent with a preserved fibrinogen
receptor function. Classification of type 1 and type 2
GT has been an appropriate method for identifying GT
patients and comparing clinical symptoms with molecular
abnormalities [10].
Type 3 GT (variant type) is defined as patients
presenting the clinical phenotype of GT but expressing
CD41a/CD61 in amounts greater than 20% that normally
support platelet aggregation [7,10,11]. It is characterized
by a lack of activated platelets due to antibodies or soluble
fibrinogen, which identify factors related to activation on
αIIbβ3 integrin. It is often caused by a single amino acid
change and is defined by the residual functional response
of platelets [10].
GT may manifest itself shortly after birth. It starts
with purpura in the newborn, followed by attacks of
mucocutaneous bleeding and spontaneous bruising. Most
patients are diagnosed before the age of 5 years. Recurrent
episodes of epistaxis occur and one of the most common
symptoms has been reported to be gingival bleeding. Fatal
bleeding episodes occur during a lifetime of a patient with
GT, while the prevalence of severe bleeding decreases
with age [12]. There is insufficient evidence to support the
relationship between gene defect in GT and the severity
of bleeding, as affected individuals show different bleeding
tendencies, even in the same family or ethnic group [7].
Although the exact number is unknown, one out
of every one million individuals is estimated to be GT
[13,14]. Studies have shown that GT is more common in
women than men probably due to severe menorrhagia
female cases are diagnosed. Approximately 58% of GT
cases are women and 42% are men [12]. Although GT can

be seen in all communities around the world, it is more
common in ethnic groups such as Iraqi Jews, Palestinians,
and French Gypsies, where consanguinity rates are high
[15,16].
The aim of our study was to confirm the diagnosis of
GT and to determine the subgroups of 32 Turkish GT
patients with flow cytometry.
2. Materials and methods
2.1. Patients and controls
Ambient EDTA blood samples of the patients with GT
and control samples were shipped from four pediatric
hematology centers (Kocaeli, Samsun, İstanbul, Kayseri)
to the laboratory. All patients had mucosal bleeding
(epistaxis, gingival bleeding, and/or menorrhagea)
requiring treatment. Platelet counts and platelet
morphology were normal, bleeding time was prolonged,
activated partial thromboplastin time (PTT), prothrombin
time, and assessments for von Willebrand disease such
as von Willebrand factor (vWF) antigen, ristocetin
cofactor activity, and factor VIII coagulant activity were
normal. Light transmission aggregometry showed absent
aggregation to all agonists other than to ristocetin (ADP,
collagen, thrombin, and arachidonic acid). Healthy
volunteers who have no coagulapathy and did not use any
drug were choosen as controls. During the flow cytometry
evaluation, samples of GT patients and control samples
were studied in the same run. Mutations in genes (ITGA2B
or ITGB3) encoding GP IIb or GP IIIa proteins of GP IIb/
IIIa complexes on the platelet surface were detected in all
patients. Among those detected, there are c. 1752 + 2T> C
(especially in type 1 GT patients), c. 1772A> C (especially
in type 2 GT patients), c. 1697G> A (especially in type 3
GT patients), and 5 novel mutations (especially in type 1
GT patients) previously unidentified (data not shown).
2.2. Laboratory work-up
Three-mililiter EDTA blood samples were centrifuged at
200 g for 10 min at room temperature and the upper two
thirds of the PRP was removed into a seperate tube. PRP
was then centrifuged once again at 200 g for 10 min in
order to concentrate the platelets further.
2.3. Antibodies and reagents
The monoclonal antibodies including FITC Mouse IgG1κ
(clone: MOPC-21), PE Mouse IgG1κ (clone: MOPC-21),
PerCP Mouse IgG1κ (clone: MOPC-31C), FITC labeled
anti-human CD41a (clone: HIP8), PE labeled antihuman
CD42b (clone: HIP1), PerCP labeled antihuman CD61
(clone: RUU-PL7F12), and CellWASH (catalog no:349524,
used for cell washing process) were obtained from BD
Biosciences (San Jose, CA, USA).
2.4. Flow cytometry
Two tubes were prepared for each control and patient
sample. 100 µL PRP were incubated with 5 µL of

2137

SARAYMEN et al. / Turk J Med Sci
monoclonal antibodies FITC Mouse IgG1κ, PE Mouse
IgG1κ, PerCP Mouse IgG1κ in the first tube and 5 µL of
monoclonal antibodies FITC labeled anti-human CD41a,
PE labeled antihuman CD42b, PerCP labeled antihuman
CD61 in the second tube for 15 min at room temperature
and in the dark. After incubation, 2 mL of CellWASH was
added to the tubes and centrifuged at 3000 g for 5 min
at room temperature. Supernatant was discarded carefully
and then 200 µL of CellWASH were added to each tube.
After that tubes were directly placed on the flow cytometer
(FACSCanto II, Becton Dickinson, Franklin Lakes,
NJ, USA). Analyzes and interpretations were carried
out by counting 50,000 events in the BD FACS Diva
Software v:6.1.3 program of the instrument. Fluorescence
measurement was evaluated as the percentage of positive
cells above a threshold set with the isotype control tube
acting as negative control. Compensation for fluorochrome
spectral overlap was adjusted for analysis. Control and
patient samples were studied in the same run.
2.5. Statistical analysis
The datas were obtained using Microsoft Office Excel 2016
program and were expressed as median and minimummaximum values.
3. Results
3.1. Clinical and demographic characteristics of patients
Thirty-two patients from 23 families (18 males, 14 females)
were included in the study. Patients’ age during the study
was 5–28 years (median 12 years). Healthy volunteers (12
males, 10 females, 6–43 years, median 13.5 years) who have
no coagulapathy and did not use any drug were controls.
Bleeding manifestations included epistaxis in 23 patients,
gum bleeding in 18 patients, easy brusing in 22 patients,
menorrhagia in 12 patients, bleeding at the injection
site in 18 patients, and haematuria in 4 patients. History
of consanguinity could be revealed in 20 of 23 families
(86.9%). The age and sex distribution of the patient group
was similar to the control group.
3.2. Results of flow cytometry analysis
Flow-cytometry analysis of 32 Turkish GT patients from
23 families and 22 control samples were determined at the
Erciyes University Mehmet-Kemal Dedeman HematologyOncology Hospital Flow Cytometry and Cell Processing
Laboratory.
FITC Mouse IgG1κ, PE Mouse IgG1κ, and PerCP
Mouse IgG1κ isotype controls were used to analyze each
patient and control sample (Figure 1a). CD41a, CD42b,
CD61, and CD41a/CD61 expression levels in controls and
GT patients were assessed in PRP (Figures 1b–1e).
Expression levels of CD41a, CD42b, CD61 and
CD41a/CD61 in control samples were 95.8% to 100%
(median: 99.7), 94.3% to 100% (median: 98.9), 93.8% to
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100% (median: 99.5), and 93.8% to 100% (median: 99.1),
respectively.
In this analysis, 19 out of 32 patients were consistent
with type 1 GT (59.4%), 4 were consistent with type 2 GT
(12.5%), and 9 were consistent with type 3 GT (28.1%).
Expression levels of CD41a, CD42b, CD61 and
CD41a/CD61 in type 1 GT patients were 0% to 5.2%
(median: 0.6), 88.4% to 98.5% (median: 92), 8.6% to 74.7%
(median: 21.4), and 0% to 4.6% (median: 0.3), respectively.
CD41a expression level was found to be lower than CD61
expression level in all type 1 GT patients. Expression
levels of CD41a, CD42b, CD61, and CD41a/CD61 in
type 2 GT patients were 14.1% to 18.9% (median: 15.8),
93.5% to 97.3% (median: 94.6), 53.2% to 98.5% (median:
62.9), and 12.5% to 18.7% (median: 13.6), respectively.
CD41a expression level was found to be lower than CD61
expression level in all type 2 GT patients as well. Expression
levels of CD41a, CD42b, CD61, and CD41a/CD61 in type
3 GT patients were 48.6% to 98.2% (median: 87.2), 94.1%
to 98.3% (median: 96.9), 57.1% to 85.1% (median: 64.8),
and 35.4% to 84.8% (median: 61), respectively. In contrast
to type 1 and type 2 GT patients, CD61 expression level
was lower than CD41a expression level in this patient
group.
The distribution of CD41a and CD61 expression levels
in patient and control groups were shown in (Figure 2).
4. Discussion
CD41a and CD61 receptors on the platelet surface are
adhesion molecules involved in the platelet aggregation
process. GT is a hereditary platelet disorder characterized
by bleeding diathesis as a result of a defect in the synthesis
of these receptors (failure to synthesize by mutation or
closure with autoantibody) [17]. In our study, epistaxis
(71.9%) and easy bruising (68.8%) were among the
most common presenting symptoms. Menorrhagia was
found to be one of the most common clinical findings in
adolescent girls. These findings were similar to the studies
in the literature [17–19].
In GT, the incidence of severe bleeding in general
decreases with age [20]. No correlation between the levels
of GP IIb/IIIa and severity of bleeding was reported [7,21].
In a study by Kutlubay et al. in 2012, out of 15 Turkish GT
cases 7, 6 and 2 of the patients were compatible with type
1, type 2, and type 3, respectively [22]. In 2015, Tokgöz et
al. reported that out of 20 Turkish GT patients, 18 and 2
cases were compatible with type 1, and type 2, respectively
[23].
In the present study, flow cytometry analysis showed
that 12 out of 23 families were consistent with type 1 GT
(52.2%), 4 were consistent with type 2 GT (17.4%), and 7
were consistent with type 3 GT (30.4%). Since type 1 GT is
seen in 52.2% of the GT patients, type 1 is considered to be
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CD42b PE-A

c)

SSC-A

b)

d)

e)

FSC-A

CD41a FITC-A

CD41a FITC-A

Figure 1. a) Isotype controls with null levels of IgG1κ FITC, IgG1κ PE, and IgG1κ PerCP. b) Control with normal levels of both
CD41a FITC, CD42 PE, and CD61 PerCP. c) Type 1 GT with null or reduced levels of both CD41a FITC and CD61 PerCP (<5%) and
normal levels of CD42 PE. d) Type 2 GT with reduced levels of both CD41a FITC and CD61 PerCP (5%–20%) and normal levels of
CD42 PE. e) Type 3 GT with near normal levels of CD41 FITC and CD61 PerCP and normal levels of CD42 PE.

the most common subgroup in Turkey, followed by type 3
and type 2 that is seen in 30.4% and 17.4%, respectively. The
data confirmed to the previous studies from Turkey that
type 1 GT was most common in Turkish patients [22,23].
Our results were in agreement with the result of Kannan et
al. study and Hassan et al. study that revealed the highest

frequency in type 1 GT (64% and 86%) followed by type 3
GT (24% and 11%) [24,25].
In our study CD41a expression level was found to be
lower than CD61 expression level in all type 1 and type 2
GT patients. However, CD61 expression level was lower
than CD41 expression level in type 3 GT patients. These
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Figure 2. Distribution of CD41a and CD61 expression levels in
GT subgroups and control group.

findings were similar to the studies in the literature [26].
Studies have shown that GT is more common in women
than men probably due to more females were diagnosed
due to heavy menstrual bleeding. Approximately 58% of
GT cases were women and 42% were men [12]. However,
18 of the young 32 GT patients were male (56.3%) and 14
were female (43.7%) in this study. Records of our patients
indicate that diagnosis was made in the first and second
decade of life.
GT is more common among ethnic groups, such
as Iraqi Jews, Palestinians, and French Gypsies, with
high consanguinity rates, although they can be seen in
all communities around the world. Disease was seen in
about 150 out of 300 French Gypsies [15,16]. There was
history of consanguinity in 86.9% of our families which
was consistent with the frequency of 90% reported in a
previous study from Turkey [23].
In addition to flow cytometry in the identification of
GT; western blot, dot blot, and ELISA methods have also
been reported [27–29]. Farsinejad et al. found that CD61

expression level was higher than CD41 expression level in
the western blot analysis [27]. Vijapurkar et al. emphasized
that the dot blot method could be used to diagnose type
1 GT but this method is not useful in defining other
subgroups [28]. Lobo et al. developed the ELISA method
for detecting GT. They could detect type 1 GT subgroup
but failed to identify the other subgroups by ELISA [29].
Especially due to consanguineous marriages, GT with
various glycoprotein levels may be detected. As a result of
the flow cytometry analysis of the present study with the
highest GT patient population in Turkey, type 1 GT patients
were the most common subgroup. In the determination of
the GT subgroups; especially in the detection of type 3 GT,
flow cytometry is the most sensitive glycoprotein analysis
method. In addition to light transmission aggregometry,
CD41a/CD61 study by flow cytometer confirms diagnosis
when mutation analysis cannot be performed.
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